Ekso Bionics® Partners with HASOMED to Launch Functional Electrical Stimulation (FES) for the EksoGT™ Exoskeleton
Combination of Exoskeleton and RehaStim2 FES Technology Provide Breakthrough Rehabilitative Care
RICHMOND, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced the launch of the EksoGT™ exoskeleton’s Functional Electrical Stimulation (FES) interface capability through a partnership with HASOMED, a developer of innovative products for neurological rehabilitation. Previously used for research, HASOMED’s RehaStim2 FES integration with EksoGT exoskeleton is now CE Marked and available for routine clinical use in Europe.
“At Ekso Bionics, we strategically work to improve patient outcome by continually revolutionizing rehabilitation with our exoskeleton technology,” said Thomas Looby, president and chief executive officer of Ekso Bionics. “The combination of the EksoGT and its benefits, with the RehaStim2 FES technology, provides clinicians with the latest advancements in care, which ultimately improves clinical outcomes and patient quality of life. The synergies between the two technologies mark an important step in our ability to offer an even more versatile device that enables clinicians to provide rehabilitation to a wider range of patients across different disease states, including spinal cord injuries and stroke.”
FES is a technique that uses low energy electrical pulses to artificially generate body movements in individuals who have been paralyzed due to injury to the central nervous system. Clinical practitioners in EMEA can purchase RehaStim2 through HASOMED, or as an upgrade, with training provided by Ekso Bionics. The combination of exoskeleton technology with FES, give clinicians the synergistic benefits of earlier mobility and muscle stimulation to provide rehabilitation to a broader spectrum of patients, ranging from pre-ambulatory to almost independent.
“Our RehaStim2 FES device sends electrical impulses to the muscles, generating targeted movement of extremities despite paralysis,” commented Matthias Weber, chief executive officer and owner of HASOMED. “Now, through our extended partnership with Ekso Bionics, European rehabilitation specialists will have the opportunity to provide cutting-edge combination therapy to their patients.”
The first European customer installation for the EksoGT exoskeleton with RehaStim2 FES device is slated for January 2018, and is currently available for investigational research use in the United States.
For more information about Ekso Bionics or EksoGT™, visit www.eksobionics.com.
About HASOMED GmbH
HASOMED GmbH is an owner-managed company focusing on neurological rehabilitation. Originally established in 1991 in Kronberg / Taunus, the head office was relocated in 1995 to Magdeburg. Dr. Peter Weber and Matthias Weber are owners and CEOs of the company. HASOMED GmbH are a spin-off from the Department of Science of the Medical Faculty of the University Magdeburg. Thus the focus of activities during first years of establishment was on development and manufacturing of research technology.
About EksoGT™
EksoGT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of a patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently, and with a greater number of high intensity steps. To date, this device has helped patients take more than 70 million steps in over 185 rehabilitation institutions around the world.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the ability to manage successfully and complete the rights offering, (ii) the expected proceeds of the offering, (iii) the anticipated use of proceeds from the offering, if successful, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Investor Contact:
Matthew Ventimiglia
212-599-1265
investors@eksobionics.com
Released December 14, 2017